Providing accurate information to your patients about this antirheumatic drug will help them avoid potential nocebo effects In an article written for the Medical Journal of Australia, University of Sydney physicians have outlined commonly held myths and misconceptions regarding methotrexate treatment for rheumatoid arthritis. Methotrexate is a first-line agent and disease-modifying antirheumatic drug (DMARD). It made up
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.